Evidence map›Paper›PMID 37195346›Full record

Observational studyJournal of neurology2023

Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study.

Bingyou Liu, Jianian Hu, Chong Sun, Kai Qiao, Jianying Xi, Yongsheng Zheng, Jian Sun, Sushan Luo, Yanyin Zhao, Jiahong Lu and 2 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Bingyou Liu *Department of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Jianian Hu *Department of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Chong SunDepartment of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Kai QiaoDepartment of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Jianying XiDepartment of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Yongsheng ZhengDepartment of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Jian SunDepartment of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Sushan LuoDepartment of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Yanyin ZhaoDepartment of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Jiahong LuDepartment of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Jie LinDepartment of Neuology, Huashan Hospital, Fudan University, Shanghai, China. linjie15@fudan.edu.cn.ORCID http://orcid.org/0000-0001-6351-3389
Chongbo ZhaoDepartment of Neuology, Huashan Hospital, Fudan University, Shanghai, China.
Fudan University · CN

Funding

Shanghai Municipal Science and Technology Major Project No.2018SHZDZX01
6 · The paper itself

Abstract

Autoimmune nodopathy is a peripheral neuropathy characterized by acquired motor and sensory deficit with autoantibodies against the node of Ranvier or paranodal region in the peripheral nervous system. The clinical and pathological characteristics of the disease are distinct from that of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and the standard treatment for CIDP is partially effective. Rituximab is a chimeric monoclonal antibody which binds and depletes B cells in peripheral blood. This prospective observational study included 19 patients with autoimmune nodopathy. Participants received intravenous rituximab treatment 100 mg the first day and 500 mg the next day and given every 6 months. The Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Inflammatory Rasch-Built Overall Disability Scale (I-RODS), Medical Research Council (MRC) sum score, and Neuropathy Impairment Score (NIS) were collected at entry and before the rituximab infusion every 6 months. At the last visit, 94.7% (18/19) of the patients showed clinical improvement on either the INCAT, I-RODS, MRC, or NIS scale. After the first infusion, 9 patients (47.7%) showed improvement on the INCAT score, and 11 patients (57.9%) on cI-RODS. In patients who received more than one rituximab infusion, the improvement of INCAT score and cI-RODS at the last assessment was higher than that after the first infusion. We also observed tapered or withdrawn concomitant oral medications in these patients.

Indexed as

Persons with DisabilitiesPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingCohort StudiesHumansProspective StudiesRituximabRituximabChronic inflammatory demyelinating polyradiculoneuropathyPeripheral neuropathyProspective observational studyRituximabTreatment

Identifiers

PMID37195346
OpenAlexW4376872870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.